Mizuho Medy Co.,Ltd. (TYO:4595)
1,720.00
+1.00 (0.06%)
Oct 23, 2026, 3:30 PM JST
Mizuho Medy Revenue
Mizuho Medy had revenue of 1.33B JPY in the quarter ending June 30, 2026, a decrease of -0.15%. This brings the company's total for the last twelve months to 10.82B, up 0.75% year-over-year. In the year 2025, Mizuho Medy had annual revenue of 11.26B, down -1.48%. That makes Mizuho Medy the 25,547th largest company in the world by revenue and 2,733rd in Japan.
Revenue (ttm)
10.82B
Revenue Growth
+0.75%
P/S Ratio
3.03
Revenue / Employee
56.05M
Employees
193
Market Cap
32.76B
Revenue by Segment
- Hospitals and Practitioner - New Coronavirus Test Drug 6.88B 60.2%
- Hospitals and Practitioner - Other Testing Agents and Equipment 3.19B 27.9%
- Hospitals and Practitioner - Influenza Test Drug 977.00M 8.5%
- Over-the-counter and Other Fields 382.00M 3.3%
Fiscal year ended Dec 31, 2024 See the full Mizuho Medy breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 11.26B | -169.00M | -1.48% |
| Dec 31, 2024 | 11.43B | 440.00M | 4.00% |
| Dec 31, 2023 | 10.99B | -6.59B | -37.50% |
| Dec 31, 2022 | 17.58B | 4.44B | 33.83% |
| Dec 31, 2021 | 13.14B | 8.93B | 212.41% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KYORIN Pharmaceutical | 125.68B |
| Mochida Pharmaceutical | 122.04B |
| Zeria Pharmaceutical | 91.12B |
| ASKA Pharmaceutical Holdings | 70.87B |
| Pharma Foods International | 63.22B |
| Fuso Pharmaceutical Industries,Ltd. | 62.85B |
| Fuji Pharma | 60.11B |
| Daito Pharmaceutical | 49.53B |